Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Lipid-lowering agents primarily target cholesterol but may influence other cardiovascular risk factors.
• Atherogenic pathways include inflammation, hemostasis, and blood pressure regulation.
• Understanding pleiotropic effects is crucial for comprehensive cardiovascular disease (CVD) prevention.

Purpose of the Study:

• To review the non-lipid-modifying effects of lipid-lowering agents.
• To explore the impact of these agents on inflammation, hemostasis, and blood pressure.
• To assess the contribution of these pleiotropic actions to CVD prevention.

Main Methods:

• Systematic review of existing literature on lipid-lowering agents.
• Analysis of studies investigating effects on inflammatory markers.
• Evaluation of data on hemostatic and blood pressure modulation.

Main Results:

• Most lipid-lowering agents demonstrate anti-inflammatory, antithrombotic, and antihypertensive properties.
• Statins exhibit significant pleiotropic actions contributing to reduced cardiovascular events and deep venous thrombosis.
• The role of these effects for other lipid-lowering drugs remains uncertain.

Conclusions:

• Lipid-lowering agents possess pleiotropic effects beyond lipid modification.
• These additional effects, particularly with statins, contribute to cardiovascular risk reduction.
• Further research is needed to clarify the clinical significance of pleiotropic actions for non-statin lipid-lowering therapies.